NILOTINIB D-TARTRATE
GrowthNDAORALCAPSULE
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nilotinib D-tartrate is an oral tyrosine kinase inhibitor targeting Bcr-Abl, approved February 2025 by Cipla. It is indicated for chronic myeloid leukemia (CML) and other Bcr-Abl-positive malignancies. The drug works by blocking the abnormal protein kinase activity driving leukemic cell proliferation.
Growth
Recent launch (Feb 2025) in a mature kinase inhibitor market signals active commercial buildout with hiring in sales, marketing, and market access roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Nilotinib offers exposure to high-stakes oncology commercial execution in a competitive kinase inhibitor market. This is a growth-stage product launch requiring strong payer negotiation, field force enablement, and managed care penetration skills within a mature indication.
Brand ManagerField Sales Representative
Worked on NILOTINIB D-TARTRATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.